

benefits and risks, and (5) evaluate the safety and efficacy of products under review. The consumer representative should be able to represent the consumer perspective on issues and actions before the advisory committee; serve as a liaison between the committee and interested consumers, associations, coalitions, and consumer organizations; and facilitate dialogue with the advisory committees on scientific issues that affect consumers.

III. Selection Procedures

Selection of members representing consumer interests is conducted through procedures that include the use of organizations representing the public interest and public advocacy groups. These organizations recommend nominees for the Agency's selection. Representatives from the consumer health branches of Federal, State, and local governments also may participate in the selection process. Any consumer organization interested in participating in the selection of an appropriate voting or nonvoting member to represent consumer interest should send a letter stating that interest to FDA (see **ADDRESSES**) within 30 days of publication of this document.

Within the subsequent 45 days, FDA will compile a list of consumer organizations that will participate in the selection process and will forward to each such organization a ballot listing at least two qualified nominees selected by the Agency based on the nominations received, together with each nominee's current curriculum vitae or résumé. Ballots are to be filled out and returned to FDA within 30 days. The nominee receiving the highest number of votes ordinarily will be selected to serve as the member representing consumer interests for that particular advisory committee or panel.

IV. Nomination Procedures

Any interested person or organization may nominate one or more qualified persons to represent consumer interests on the Agency's advisory committees or panels. Self-nominations are also accepted. Nominations must include a current, complete résumé or curriculum vitae for each nominee and a signed copy of the *Acknowledgement and Consent* form available at the FDA Advisory Nomination Portal (see **ADDRESSES**), and a list of consumer or community-based organizations for which the candidate can demonstrate active participation.

Nominations must also specify the advisory committee(s) or panel(s) for which the nominee is recommended. In addition, nominations must also

acknowledge that the nominee is aware of the nomination unless self-nominated. FDA will ask potential candidates to provide detailed information concerning such matters as financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest. Members will be invited to serve for terms of up to 4 years, or for less time at the discretion of the Commissioner or designee.

FDA will review all nominations received within the specified timeframes and prepare a ballot containing the names of qualified nominees. Names not selected will remain on a list of eligible nominees and be reviewed periodically by FDA to determine continued interest. After selecting qualified nominees for the ballot, FDA will provide those consumer organizations that are participating in the selection process with the opportunity to vote on the listed nominees. Only organizations vote in the selection process. Persons who nominate themselves to serve as voting or nonvoting consumer representatives will not participate in the selection process.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. 1001 *et seq.*) and 21 CFR part 14, relating to advisory committees.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–20065 Filed 9–30–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–0008]

Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is requesting nominations for qualified individuals to serve as voting members of FDA's standing public advisory committees and panels (collectively, advisory committees). This notice covers scientific, technical, professional, and other voting-member positions in which appointees serve as individuals rather than as designated representatives; it does not solicit

nominations for consumer representative or industry representative positions. FDA will consider nominations for current and future vacancies as they arise. FDA encourages nominations of all appropriately qualified candidates whose expertise and perspectives would contribute to the work and balanced composition of its advisory committees.

DATES: FDA accepts nominations on a continuing basis. Nominations received on or before November 30, 2026 will be given first consideration for current and near-term vacancies. Nominations received after that date will be considered as later vacancies arise.

ADDRESSES: Submit nominations electronically through the FDA Advisory Committee Membership Nomination Portal at <https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm> and, for positions covered by this notice, select "Academician/Practitioner" as the membership type. Nominations also may be submitted by mail to the Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3215, Silver Spring, MD 20993–0002. Information about applying for membership is available at <https://www.fda.gov/advisory-committees/advisory-committee-membership/applying-membership-fda-advisory-committees>. Information about FDA advisory committees, including committee charters and meeting materials, is available at <https://www.fda.gov/advisory-committees/committees-and-meeting-materials>.

FOR FURTHER INFORMATION CONTACT: Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3215, Silver Spring, MD 20993–0002, 301–796–8220, ACOMSSubmissions@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background and Scope

FDA uses public advisory committees to obtain independent expert advice on scientific, technical, and policy matters within the Agency's responsibilities.

This notice applies to voting-member positions in which members serve as individuals and not as representatives of a nominating or affiliated group, consistent with 21 CFR 14.82(d). It does not apply to positions designated to represent consumer or industry interests. Separate statutes, regulations, charters, or notices may govern those representative positions or other committee-specific nomination and selection processes. If a committee-

specific statute or charter establishes qualifications, composition, nomination, or selection requirements, those requirements control. This notice does not replace the solicitation of nominations required when FDA establishes a new advisory committee under 21 CFR 14.82(b).

For medical device classification panels, this annual notice also provides the opportunity described in section 513(b)(5)(D) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360c(b)(5)(D)) for patients, representatives of patients, and sponsors of medical devices that may be specifically subject to review by a classification panel to recommend individuals with appropriate expertise for voting-member positions.

II. Criteria for Voting Members and Appointment Status

In general, nominees should demonstrate subject-matter expertise relevant to one or more FDA advisory committees, the ability to interpret complex scientific or technical information, an understanding of the public health significance of the matters before the committee, and the ability to provide objective and independent advice. FDA will consider the expertise, experience, professional disciplines, and points of view needed for the functions of the particular committee and to support fairly balanced membership.

Voting members serve as individuals and not as representatives of any group or organization that nominated them or with which they are affiliated. Generally, non-Federal voting members are appointed as special Government employees and are subject to applicable Federal ethics and conflict-of-interest requirements. Federal employees may serve as regular Government employees in their official capacities when authorized for the particular committee and position. Certain committees or positions may be governed by different statutory, regulatory, or charter provisions. FDA will determine the appropriate appointment status for each position.

Members generally are invited to serve for overlapping terms of up to 4 years, or for a shorter period at the discretion of the appointing official, subject to the applicable statutes, regulations, and committee charter.

III. Nomination Procedures

Any interested person may nominate one or more qualified individuals for membership on one or more of the advisory panels or advisory committees. Self-nominations are also accepted.

Nominations must include a current, complete résumé or curriculum vitae for each nominee. Nominations must also specify the advisory committee for which the nominee is recommended. Additionally, nominations must acknowledge that the nominee is aware of the nomination unless self-nominated. FDA will ask potential candidates to provide detailed information concerning such matters related to financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest. Only U.S. Citizens, non-citizen U.S. Nationals, and Permanent Residents may apply for service as a committee member.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. 1001 *et seq.*) and 21 CFR part 14, relating to advisory committees.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–20063 Filed 9–30–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–6876]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments (including recommendations) on the collection of information by November 2, 2026.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to <https://www.reginfo.gov/public/do/PRAMain>. Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910–0922. Also include

the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:

Kelly Covington, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 240–402–5661, PRASaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Medical Devices; Voluntary Improvement Program

OMB Control Number 0910–0922—Extension

This information collection supports Food and Drug Administration (FDA, us or we) implementation of its Voluntary Improvement Program (VIP). Included among the strategic priorities of our Center for Devices and Radiological Health (CDRH) is promoting a culture of quality and organizational excellence. As communicated on our website at <https://www.fda.gov/medical-devices/quality-and-compliance-medical-devices/voluntary-medical-device-manufacturing-and-product-quality-pilot-program>, we conducted a pilot project pertaining to voluntary medical device manufacturing and product quality and have incorporated some of the successes and learnings into the VIP. The VIP oversees third-party appraisers who evaluate industry participants. The VIP is facilitated by the Medical Device Innovation Consortium (MDIC), a public-private partnership that evaluates the capability and performance of a medical device manufacturer's practices using third-party appraisals and is intended to guide improvement to enhance the quality of devices. As part of the VIP process, FDA receives information about participating device manufacturers' capability and performance for activities covered in third-party appraisals.

The guidance document entitled, “*Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program*,” communicates our policy regarding participation in the VIP. Only eligible manufacturers of medical devices regulated by CDRH whose marketing applications are reviewed under the applicable provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (including sections 510(k), 513, 515, and 520) may participate in the VIP. The guidance